Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rory Collins

Showing results (31-40 of 267) with videos related to

Pageof 27
Sort By:
European Heart Journal|May 23, 2017
UK Biobank: opportunities for cardiovascular researchThomas J Littlejohns, Cathie Sudlow, Naomi E Allen, et al.
The British Journal of Nutrition|December 25, 2008
Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servantsRobert Clarke, Martin Shipley, Jane Armitage, et al.
Lancet (London, England)|March 22, 2017
Safety and efficacy of statins - Authors' replyRory Collins, Jane Armitage, Colin Baigent, et al.
Lancet (London, England)|June 11, 2026
Challenges in assessing statin-associated adverse events - Authors' replyChristina Reith, Jonathan R Emberson, David Preiss, et al.
Clinical Chemistry|February 26, 2003
Stabilization of homocysteine in unseparated blood over several days: a solution for epidemiological studiesSarah Clark, Linda D Youngman, Joan Sullivan, et al.
Clinical Chemistry|August 27, 2002
Reliable measurement of glycated hemoglobin in frozen blood samples: implications for epidemiologic studiesLinda D Youngman, Sarah Clark, Susan Manley, et al.
The Lancet. Diabetes & Endocrinology|November 26, 2016
Are statins useful in patients with advanced chronic kidney disease? - Authors' replyWilliam G Herrington, Jonathan Emberson, Borislava Mihaylova, et al.
BMJ (Clinical Research Ed.)|November 14, 2006
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, Borislava Mihaylova, Andrew Briggs, et al.
Lancet (London, England)|May 25, 2005
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individualsBorislava Mihaylova, Andrew Briggs, Jane Armitage, et al.
Lancet (London, England)|March 6, 2004
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studiesJeremy G Wheeler, Bernard D Keavney, Hugh Watkins, et al.
Pageof 27

Showing results (31-40 of 267) with videos related to

Sort By:
Pageof 27
European Heart Journal|May 23, 2017
UK Biobank: opportunities for cardiovascular researchThomas J Littlejohns, Cathie Sudlow, Naomi E Allen, et al.
The British Journal of Nutrition|December 25, 2008
Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servantsRobert Clarke, Martin Shipley, Jane Armitage, et al.
Lancet (London, England)|March 22, 2017
Safety and efficacy of statins - Authors' replyRory Collins, Jane Armitage, Colin Baigent, et al.
Lancet (London, England)|June 11, 2026
Challenges in assessing statin-associated adverse events - Authors' replyChristina Reith, Jonathan R Emberson, David Preiss, et al.
Clinical Chemistry|February 26, 2003
Stabilization of homocysteine in unseparated blood over several days: a solution for epidemiological studiesSarah Clark, Linda D Youngman, Joan Sullivan, et al.
Clinical Chemistry|August 27, 2002
Reliable measurement of glycated hemoglobin in frozen blood samples: implications for epidemiologic studiesLinda D Youngman, Sarah Clark, Susan Manley, et al.
The Lancet. Diabetes & Endocrinology|November 26, 2016
Are statins useful in patients with advanced chronic kidney disease? - Authors' replyWilliam G Herrington, Jonathan Emberson, Borislava Mihaylova, et al.
BMJ (Clinical Research Ed.)|November 14, 2006
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, Borislava Mihaylova, Andrew Briggs, et al.
Lancet (London, England)|May 25, 2005
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individualsBorislava Mihaylova, Andrew Briggs, Jane Armitage, et al.
Lancet (London, England)|March 6, 2004
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studiesJeremy G Wheeler, Bernard D Keavney, Hugh Watkins, et al.
Pageof 27